Clinical Trial Search

Primary: Seroconversion Rate 21 Days After First Study Vaccination — 4.0; 88.2; 83.1; 3.7 Percentage of participants

Primary: The Safety and Tolerability of a Single-dose of KB001. — 7; 10; 8 Number of participants experiencing AEs

Primary: Clinical Tumor Regression — 1 Participants

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test — 1.2; 7.5; 9.7; 6.9 percent change

Primary: Number of Participants Achieving Pathological Complete Response — 0 participants

Primary: Change in Levels of Insulin Like Growth Factor-1 (IGF-I) Following Recombinant Human (rh) IGF-1 Administration in Girls With Anorexia Nervosa — 542.9 ng/ml — p=<0.05

Primary: Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study…

Primary: Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8. — 1; 1…

Primary: The Number of Subjects With Adverse Events — 10 participants

Primary: Number of Participants With Objective Tumor Response Through Week 16 — 5 Participants

Primary: The Relative Change in Peak Systolic Radial Strain of the Left Ventricle (LV) Inferolateral Wall From Baseline (at Screening) to Week 52, Assessed by Color Doppler…

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Premature Discontinuation of Study or Study Drug Due to Any Reason — 4; 6; 3 Participants

Primary: Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment — 28; 16 participants